A Phase 3 interventional study of 13-valent Pneumococcal Conjugate Vaccine and 7 valent pneumococcal conjugate vaccine in Pneumococcal Infections, sponsored by Pfizer. Completed at 5 sites in Israel. Open to participants aged 42 Days to 98 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-05-10.
Sponsored by Pfizer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections — none open to participants now, 1 under way, none of them phase 3. 13-valent pneumococcal vaccine · Pneumococcal Infections.
Among the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections, this one is the 4th largest by enrollment, is one of 6 that started in 2007, is one of 19 in phase 3, and was the 7th registered.
298 studies on the registry are indexed under Pneumococcal Infections; 25 are open to participants now.
Browse Pneumococcal Infections studies →None of the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections is open now. The open studies under Pneumococcal Infections, anywhere →
13-valent pneumococcal vaccine: first FDA approval 2010 (Prevnar 13). What it is approved for, and how studies give it, is on its page →
Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.
This study: 42 Days to 98 Days · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 20 · Phase 4 11
First in 2004; this study’s year is marked. 6 started in 2007.
This study's enrollment of 1,866 is above the median of 373 across 253 interventional studies indexed under Pneumococcal Infections.
Median enrollment 328 across the 44 interventional studies. Of the 40 that completed or were terminated, 23 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 44 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
75 studies in Pneumococcal Infections by Pfizer: 4 open now, 8 under way, 5 of them phase 3. Of 67 finished, 45 (67%) have results posted.
Among the 75 studies in Pneumococcal Infections by Pfizer, this one is the 8th largest by enrollment of the 57 interventional ones that give a count, is one of 7 that started in 2007, is one of 33 in phase 3, and was the 17th registered.
Pfizer’s Pneumococcal Infections studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections, from their registry updates:
Among Pfizer’s 75 in Pneumococcal Infections:
This tab as a report to print or save as PDF → With an account.
This study is designed to assess the impact of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) on nasopharyngeal colonization with Streptococcus pneumoniae in healthy infants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
13 valent pneumococcal conjugate vaccine
Biological: 13-valent Pneumococcal Conjugate Vaccine
7 valent pneumococcal conjugate vaccine
Biological: 7 valent pneumococcal conjugate vaccine
1 dose at 2, 4, 6 and 12 months of age
Also known as: 13vPnC
1 dose at 2, 4, 6 and 12 months of age
Also known as: 7vPnC
Percentage of Participants With a New Acquisition of Serotype 6A' (6A + 6C) or 19A Combined 1 Month After the Infant Series to 24 Months of Age
A new acquisition was defined as the detection of a serotype (here 6A' \[6A + 6C\] or 19A), once a participant was fully vaccinated (one month after dose 3), that had not been detected previously in the baseline samples at 2, 4, 6 months of age.
Time frame: Month 7 through Month 24
Percentage of Participants With Nasopharyngeal Cultures Testing Positive for 6A' (6A + 6C) or 19A Serotypes of Streptococcus Pneumoniae (S. Pneumoniae) at 7, 12, 13, 18 and 24 Months of Age
Time frame: Month 7, 12, 13, 18, 24
| Milestone | 13vPnC | 7vPnC |
|---|---|---|
| Started | 932 | 934 |
| Vaccinated dose 1 (at 2 months of age) | 930 | 933 |
| Vaccinated dose 2 (at 4 months of age) | 904 | 902 |
| Vaccinated dose 3 (at 6 months of age) | 898 | 892 |
| Completed | 890 | 889 |
| Not completed | 42 | 45 |
| Withdrew: Adverse event | 5 | 4 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Parent/legal guardian request | 31 | 40 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Other | 4 | 1 |
| Milestone | 13vPnC | 7vPnC |
|---|---|---|
| Started | 890 | 889 |
| Completed | 883 | 878 |
| Not completed | 7 | 11 |
| Withdrew: Adverse event | 2 | 6 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Parent/legal guardian request | 0 | 3 |
| Withdrew: Failed to return | 1 | 0 |
| Withdrew: Other | 2 | 1 |
| Milestone | 13vPnC | 7vPnC |
|---|---|---|
| Started | 883 | 878 |
| Completed | 858 | 863 |
| Not completed | 25 | 15 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Lost to follow-up | 2 | 3 |
| Withdrew: Parent/legal guardian request | 17 | 8 |
| Withdrew: Other | 5 | 4 |
A new acquisition was defined as the detection of a serotype (here 6A' \[6A + 6C\] or 19A), once a participant was fully vaccinated (one month after dose 3), that had not been detected previously in the baseline samples at 2, 4, 6 months of age.
| percentage of participants | 13vPnC | 7vPnC |
|---|---|---|
| Percentage of Participants With a New Acquisition of Serotype 6A' (6A + 6C) or 19A Combined 1 Month After the Infant Series to 24 Months of Age | 20.0 (17.4 to 22.8) | 36.0 (32.8 to 39.3) |
| percentage of participants | 13vPnC | 7vPnC |
|---|---|---|
| Month 7 (n= 881, 871) | 7.3 (5.6 to 9.2) | 10.9 (8.9 to 13.2) |
| Month 12 (n= 881, 873) | 8.1 (6.3 to 10.1) | 13.7 (11.5 to 16.2) |
| Month 13 (n= 871, 870) | 5.4 (4.0 to 7.1) | 13.6 (11.4 to 16.0) |
| Month 18 (n= 864, 864) | 7.1 (5.4 to 9.0) | 13.5 (11.3 to 16.0) |
| Month 24 (n= 855, 856) | 6.2 (4.7 to 8.0) | 10.7 (8.8 to 13.0) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Infant Series 13vPnC | — | 64/930 (6.9%) | 454/930 (48.8%) |
| Infant Series 7vPnC | — | 57/933 (6.1%) | 433/933 (46.4%) |
| After Infant Series 13vPnC | — | 48/929 (5.2%) | 290/929 (31.2%) |
| After Infant Series 7vPnC | — | 64/931 (6.9%) | 324/931 (34.8%) |
| Toddler Dose 13vPnC | — | 15/882 (1.7%) | 238/882 (27%) |
| Toddler Dose 7vPnC | — | 23/875 (2.6%) | 240/875 (27.4%) |
| After Toddler Dose 13vPnC | — | 91/882 (10.3%) | 462/882 (52.4%) |
| After Toddler Dose 7vPnC | — | 73/875 (8.3%) | 455/875 (52%) |
| Event | Infant Series 13vPnC | Infant Series 7vPnC | After Infant Series 13vPnC | After Infant Series 7vPnC | Toddler Dose 13vPnC | Toddler Dose 7vPnC | After Toddler Dose 13vPnC | After Toddler Dose 7vPnC |
|---|---|---|---|---|---|---|---|---|
| GastroenteritisInfections and infestations | 11/930 | 8/933 | 12/929 | 13/931 | 3/882 | 4/875 | 13/882 | 14/875 |
| VomitingGastrointestinal disorders | 2/930 | 5/933 | 2/929 | 0/931 | 0/882 | 4/875 | 14/882 | 7/875 |
| Otitis mediaInfections and infestations | 3/930 | 5/933 | 9/929 | 10/931 | 1/882 | 3/875 | 13/882 | 11/875 |
| PyrexiaGeneral disorders | 8/930 | 4/933 | 6/929 | 4/931 | 0/882 | 4/875 | 11/882 | 10/875 |
| BronchiolitisInfections and infestations | 10/930 | 8/933 | 3/929 | 4/931 | 0/882 | 0/875 | 1/882 | 1/875 |
| PneumoniaInfections and infestations | 2/930 | 1/933 | 5/929 | 7/931 | 0/882 | 1/875 | 9/882 | 5/875 |
| Febrile convulsionNervous system disorders | 1/930 | 2/933 | 3/929 | 5/931 | 1/882 | 1/875 | 7/882 | 8/875 |
| DehydrationMetabolism and nutrition disorders | 1/930 | 1/933 | 1/929 | 0/931 | 0/882 | 2/875 | 8/882 | 6/875 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 2/930 | 0/933 | 3/929 | 1/931 | 1/882 | 2/875 | 7/882 | 5/875 |
| Lower respiratory tract infectionInfections and infestations | 1/930 | 4/933 | 5/929 | 4/931 | 0/882 | 1/875 | 3/882 | 1/875 |
| Event | Infant Series 13vPnC | Infant Series 7vPnC | After Infant Series 13vPnC | After Infant Series 7vPnC | Toddler Dose 13vPnC | Toddler Dose 7vPnC | After Toddler Dose 13vPnC | After Toddler Dose 7vPnC |
|---|---|---|---|---|---|---|---|---|
| Otitis mediaInfections and infestations | 165/930 | 137/933 | 176/929 | 195/931 | 93/882 | 92/875 | 267/882 | 246/875 |
| PyrexiaGeneral disorders | 216/930 | 194/933 | 32/929 | 37/931 | 90/882 | 89/875 | 64/882 | 68/875 |
| PharyngitisInvestigations | 12/930 | 24/933 | 35/929 | 32/931 | 34/882 | 27/875 | 112/882 | 114/875 |
| RestlessnessPsychiatric disorders | 98/930 | 89/933 | 0/929 | 0/931 | 11/882 | 11/875 | 1/882 | 0/875 |
| PneumoniaInfections and infestations | 16/930 | 14/933 | 21/929 | 25/931 | 7/882 | 13/875 | 57/882 | 58/875 |
| Upper respiratory tract infectionInfections and infestations | 13/930 | 5/933 | 12/929 | 15/931 | 2/882 | 11/875 | 37/882 | 43/875 |
| DiarrhoeaGastrointestinal disorders | 16/930 | 9/933 | 13/929 | 8/931 | 4/882 | 7/875 | 25/882 | 34/875 |
| CoughRespiratory, thoracic and mediastinal disorders | 11/930 | 4/933 | 8/929 | 10/931 | 4/882 | 1/875 | 31/882 | 20/875 |
| LeukocytosisBlood and lymphatic system disorders | 6/930 | 9/933 | 13/929 | 17/931 | 4/882 | 4/875 | 15/882 | 15/875 |
| Urinary tract infectionInfections and infestations | 11/930 | 16/933 | 10/929 | 5/931 | 2/882 | 3/875 | 10/882 | 6/875 |
| Age Continuous(years) | 13vPnC | 7vPnC | Total |
|---|---|---|---|
| Mean | 2.2 ± 0.3 | 2.2 ± 0.3 | 2.2 ± 0.3 |
| Sex: Female, Male(Participants) | 13vPnC | 7vPnC | Total |
|---|---|---|---|
| Female | 474 | 471 | 945 |
| Male | 458 | 463 | 921 |
The record gives a start of Dec 2007, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2012, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 13-valent pneumococcal vaccine